NeoGenomics (Nasdaq:NEO) - Cours de l'action, nouvelles et analyse

NEO Aperçu des actions

NeoGenomics, Inc. exploite un réseau de laboratoires de dépistage du cancer aux États-Unis et au Royaume-Uni. Plus de détails

NEO analyse fondamentale
Score flocon de neige
Évaluation	2/6
Croissance future	1/6
Performances passées	0/6
Santé financière	4/6
Dividendes	0/6

Récompenses

Se négocie à 74.6% en dessous de notre estimation de sa juste valeur

Les revenus devraient augmenter 10.08% par an

Analyse des risques

Actuellement non rentable et ne devrait pas le devenir au cours des 3 prochaines années

NeoGenomics, Inc. Concurrents

Addus HomeCare

NasdaqGS:ADUS

US$2.2b

GeneDx Holdings

NasdaqGS:WGS

US$2.2b

Agiliti

NYSE:AGTI

US$1.4b

Astrana Health

NasdaqCM:ASTH

US$2.1b

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour NeoGenomics
Historique des cours de bourse
Prix actuel de l'action	US$16.39
Plus haut sur 52 semaines	US$21.22
Plus bas sur 52 semaines	US$12.77
Bêta	1.18
1Variation sur 1 mois	25.40%
Variation sur 3 mois	0.061%
Variation sur 1 an	-14.99%
3Variation sur 3 ans	-55.28%
Variation sur 5 ans	-36.50%
Évolution depuis l'introduction en bourse	530.38%

Nouvelles et mises à jour récentes

NeoGenomics, Inc. (NASDAQ:NEO) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable

Nov 23

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Oct 16

Recent updates

NeoGenomics, Inc. (NASDAQ:NEO) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable

Nov 23

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Oct 16

Investors Appear Satisfied With NeoGenomics, Inc.'s (NASDAQ:NEO) Prospects As Shares Rocket 29%

Aug 01

Risks To Shareholder Returns Are Elevated At These Prices For NeoGenomics, Inc. (NASDAQ:NEO)

Jul 16

NeoGenomics (NASDAQ:NEO) Is Making Moderate Use Of Debt

Apr 18

We Think NeoGenomics (NASDAQ:NEO) Has A Fair Chunk Of Debt

Jan 10

NeoGenomics: Market Punishment Continues, But Looks Justified

Sep 30

NeoGenomics grants CEO restricted shares, stock options

Aug 17

Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt

Aug 10

NeoGenomics rises ~14% on strong Q2 result

Aug 09

NeoGenomics gets new CEO

Jul 21

NeoGenomics: Refrain From Portfolio Allocation, Negligible Upside Potential

Jun 28

Is NeoGenomics (NASDAQ:NEO) Using Too Much Debt?

Apr 22

Neogenomics: Poor Performance, CEO Departure Create Downward Share Price Spiral

Apr 08

Why NeoGenomics, Inc. (NASDAQ:NEO) Could Be Worth Watching

Feb 11

Is NeoGenomics (NASDAQ:NEO) Weighed On By Its Debt Load?

Jan 07

NeoGenomics: Gambling On Growth

Dec 16

Rendement pour les actionnaires

	NEO	US Healthcare	US Marché
7D	9.0%	1.6%	2.2%
1Y	-15.0%	2.1%	31.6%

Rendement vs Industrie: NEO a sous-performé le secteur US Healthcare qui a rapporté 2.1 % au cours de l'année écoulée.

Rendement vs marché: NEO a sous-performé le marché US qui a rapporté 31.6 % au cours de l'année écoulée.

Volatilité des prix

Is NEO's price volatile compared to industry and market?
NEO volatility
NEO Average Weekly Movement	5.9%
Healthcare Industry Average Movement	6.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Cours de l'action stable: NEO n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de NEO ( 6% ) est restée stable au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
2001	2,100	Chris Smith	www.neogenomics.com

NeoGenomics, Inc. exploite un réseau de laboratoires de dépistage du cancer aux États-Unis et au Royaume-Uni. Ses activités s'articulent autour des services cliniques et des diagnostics avancés. La société propose des services d'analyse aux hôpitaux, aux centres universitaires, aux pathologistes, aux oncologues, aux cliniciens, aux sociétés pharmaceutiques et aux laboratoires cliniques.

NeoGenomics, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de NeoGenomics se comparent-ils à sa capitalisation boursière ?
NEO statistiques fondamentales
Capitalisation boursière	US$2.10b
Bénéfices(TTM)	-US$77.73m
Recettes(TTM)	US$644.12m

3.3x

Ratio P/S

-27.1x

Ratio P/E

Le site NEO est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
NEO compte de résultat (TTM)
Recettes	US$644.12m
Coût des recettes	US$363.69m
Marge brute	US$280.43m
Autres dépenses	US$358.16m
Les revenus	-US$77.73m

Derniers bénéfices déclarés

Sep 30, 2024

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	-0.61
Marge brute	43.54%
Marge bénéficiaire nette	-12.07%
Ratio dettes/capitaux propres	59.5%

Quelles ont été les performances à long terme de NEO?

Voir les performances historiques et les comparaisons

NEO Aperçu des actions

Récompenses

Analyse des risques

NeoGenomics, Inc. Concurrents

NasdaqGS:ADUS

US$2.2b

NasdaqGS:WGS

US$2.2b

NYSE:AGTI

US$1.4b

NasdaqCM:ASTH

US$2.1b

Historique des prix et performances

Nouvelles et mises à jour récentes

NeoGenomics, Inc. (NASDAQ:NEO) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable

Third quarter 2024 earnings: EPS exceeds analyst expectations

Neogenomics, Inc. Revises Full-Year 2024 Guidance

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

NeoGenomics, Inc. to Report Q3, 2024 Results on Nov 05, 2024

NeoGenomics, Inc. Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia

Recent updates

NeoGenomics, Inc. (NASDAQ:NEO) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable

Third quarter 2024 earnings: EPS exceeds analyst expectations

Neogenomics, Inc. Revises Full-Year 2024 Guidance

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

NeoGenomics, Inc. to Report Q3, 2024 Results on Nov 05, 2024

NeoGenomics, Inc. Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia

Consensus EPS estimates fall by 15%

Investors Appear Satisfied With NeoGenomics, Inc.'s (NASDAQ:NEO) Prospects As Shares Rocket 29%

NeoGenomics, Inc. Revises Earnings Guidance for the Full-Year 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

NeoGenomics, Inc. to Report Q2, 2024 Results on Jul 29, 2024

NeoGenomics, Inc. to Introduce Comprehensive Lung Solution & Feature Hematopathology Services At ASCO

NeoGenomics, Inc. Reaffirms Consolidated Earnings Guidance for the Full Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

NeoGenomics, Inc. Announces Eliminates of Position of Vishal Sikri, President, Advanced Diagnostics

NeoGenomics, Inc. to Report Q1, 2024 Results on Apr 30, 2024

NeoGenomics, Inc., Annual General Meeting, May 23, 2024

Investors Interested In NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues

Price target increased by 7.2% to US$21.55

Full year 2023 earnings: EPS exceeds analyst expectations

NeoGenomics, Inc. Provides Earnings Guidance for the Year 2024

NeoGenomics, Inc. to Report Q4, 2023 Results on Feb 20, 2024

NeoGenomics Laboratories, Inc. to Appeal Ruling

Investor Optimism Abounds NeoGenomics, Inc. (NASDAQ:NEO) But Growth Is Lacking

Consensus estimates of losses per share improve by 11%

NeoGenomics, Inc. Revises Earnings Guidance for the Full Year Ending December 31, 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Neogenomics, Inc. Announces the Commercial Availability of Two New Tests, Expanding Its Next-Generation Sequencing and Lung Cancer Portfolios

NeoGenomics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

NeoGenomics, Inc. Revises Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Risks To Shareholder Returns Are Elevated At These Prices For NeoGenomics, Inc. (NASDAQ:NEO)

NeoGenomics, Inc. Expands Board of Directors with Appointments of Three Independent Directors

NeoGenomics, Inc.'s RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage

NeoGenomics, Inc. and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer

NeoGenomics, Inc. to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO

Price target increased by 7.7% to US$21.64

NeoGenomics, Inc. Revises Earnings Guidance for the Fiscal Year 2023

First quarter 2023 earnings released: US$0.25 loss per share (vs US$0.40 loss in 1Q 2022)

NeoGenomics (NASDAQ:NEO) Is Making Moderate Use Of Debt

Full year 2022 earnings: EPS and revenues exceed analyst expectations

NeoGenomics, Inc. Announces Results of a New Study of the RaDaR Assay in Patients with Muscle-Invasive Bladder Cancer

Neogenomics, Inc. Announces Resignation of David J. Daly to Board of Directors

The Klein Law Firm Announces Lead Plaintiff Deadline of February 6, 2023 in the Class Action Filed on Behalf of Neogenomics, Inc. Shareholders

We Think NeoGenomics (NASDAQ:NEO) Has A Fair Chunk Of Debt

Gibbs Law Group Announces Files Class Action Lawsuit Against NeoGenomics Inc

NeoGenomics, Inc. Announces Executive Changes

Neogenomics, Inc. Announces Radar Assay Demonstrates Clinical Potential for Detecting Disease Recurrence Across All Types of Early Breast Cancer, Including Triple Negative Disease

NeoGenomics, Inc. Appoints Melody Harris as President, Enterprise Operations effective December 5, 2022

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

NeoGenomics Appoints David Perez to its Board of Directors

NeoGenomics, Inc. Provides Update on MolDX Submission for CRC and RaDaR(TM) Commercial Launch

NeoGenomics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

NeoGenomics: Market Punishment Continues, But Looks Justified

NeoGenomics grants CEO restricted shares, stock options

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations